TCGA-D8-A3Z6-01A-11R-A239-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 19
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.370
- WNT_BETA_CATENIN_SIGNALING+0.360
- NOTCH_SIGNALING+0.350
- MYOGENESIS+0.280
- HEDGEHOG_SIGNALING+0.270
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.260
- ESTROGEN_RESPONSE_EARLY+0.240
- FATTY_ACID_METABOLISM+0.200
- P53_PATHWAY+0.190
- ESTROGEN_RESPONSE_LATE+0.170
Top 10 suppressed
- E2F_TARGETS-0.620
- G2M_CHECKPOINT-0.540
- MYC_TARGETS_V1-0.490
- ALLOGRAFT_REJECTION-0.470
- SPERMATOGENESIS-0.310
- INFLAMMATORY_RESPONSE-0.300
- INTERFERON_GAMMA_RESPONSE-0.270
- MITOTIC_SPINDLE-0.270
- IL6_JAK_STAT3_SIGNALING-0.260
- MTORC1_SIGNALING-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-73-4675-01A-01R-1206-07 | — | cohortA2 | 0.818 |
| 2 | SRR8518125 | — | F | 0.809 |
| 3 | 1e82995c-f318-4225-96d4-f1e98bcbf60b | — | — | 0.803 |
| 4 | s0095179 | — | — | 0.802 |
| 5 | 3698f158-b7ab-4ad0-9064-ee1269a17821 | — | — | 0.799 |
| 6 | TCGA-IQ-7631-01A-11R-2081-07 | — | — | 0.788 |
| 7 | SRR35579814 | — | A | 0.782 |
| 8 | ac271c9e-4219-4880-ad89-0df6d5df0bb4 | — | — | 0.771 |
| 9 | MBCProject_3672_T1_RNA | — | B | 0.769 |
| 10 | SRR2661579 | — | — | 0.758 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.370 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.360 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.350 | Inavolisib | — uncovered |
| MYOGENESIS | 0.280 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.270 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.260 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.240 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.190 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.170 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.160 | Inavolisib | — uncovered |
| COAGULATION | 0.150 | Binimetinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.150 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.130 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_DN | 0.100 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.090 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.090 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.050 | Inavolisib | — uncovered |
| HYPOXIA | 0.040 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.030 | Inavolisib | — uncovered |